Inclusive clinical trials enable more patients to benefit from therapies that can improve their quality of life. However, an under-representation of racial and ethnic minority groups in clinical trials has been, and continues to be, a major issue within the U.S. healthcare system.
“Disparities in clinical research participation are well documented and, like many other healthcare disparities, are a byproduct of systemic and institutional racism,” said LUNGevity Foundation Chief Health Equity Officer Jeanne Regnante. “The COVID-19 vaccine and treatment development have amplified the need for all communities to have the same opportunities to participate in research and benefit from new scientific advancements.”
To address this challenge, health care and community leaders at National Cancer Institute (NCI)-designated cancer centers, advocacy organizations such as LUNGevity Foundation and Stand Up To Cancer, and digital engagement specialists PlatformQ Health are collaborating to support more inclusive clinical research.
Interested in learning more about our approach to improving diversity in clinical trial participation? Email us at firstname.lastname@example.org.